Targeting the Metabolic Mechanisms of MASLD and MASH: A Fresh Horizon for Improved Outcomes

Description

Supported by: Novo Nordisk

Organized by: Institute for Medical and Nursing Education Inc.

Presenters:

Naim Alkhouri, MD

Sonal Kumar, MD, MPH

Octavia Pickett-Blakely, MD, MHS

Join us for a highly interactive symposium featuring multiple opportunities for audience-expert interaction, including case studies and a question-and-answer session. Learners will hear expert faculty summarize the current understanding of metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), their relationship with other metabolic disorders, and guideline recommendations for diagnosis and management. There will also be an overview of emerging noninvasive tests for detecting “at-risk” MASH in specialty care. Next, learners will be given the opportunity to put this information to the test in the “What Would You Do?” segment, where they will be challenged to make clinical decisions for people with MASLD/MASH. All symposium learners will have the opportunity to participate in small group virtual practice clinics after the symposium – discussing clinical practice with one of the expert faculty!

Learning Objectives:  

1. Explain the metabolic mechanisms that link MASLD/MASH, type 2 diabetes, and obesity, and the role of guideline recommended agents in targeting common disease pathways
2. Critically review the evidence supporting use of treatments with proven efficacy in MASLD/MASH, including weight management strategies and pharmacotherapies with cardiometabolic benefits
3. Implement evidence-based guideline and clinical care pathway recommendations for the management of MASLD/MASH, including screening and monitoring, early implementation of appropriate pharmacotherapy, and collaboration with other specialists where relevant

CME Hours: Maximum 1.5 AMA PRA Category 1 Credits™

For more information and to register, visit: www.liver.imne.com